RxDoctor Payments Data

Christopher Thomas, MD

Pulmonary Disease · Baton Rouge, LANPI 1366486292

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Abiomed at 32.0% of the total. Reporting peaked in 2022 at $281 and has fallen 78.0% since, to $62 in 2025. That places this record below the midpoint for pulmonary disease clinicians in LA, where the typical reported total is $3,696.

$569in general payments, 2019–2025

Across 15 payments — averaging $37.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$182
  • Rxsight Inc$136
  • AbbVie$112
  • Masimo Corporation$50
  • Sanofi$37
  • Abbott$24
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed2$182
Rxsight Inc1$136
AbbVie(2 entities)6$112
Masimo Corporation2$50
Sanofi1$37
Abbott1$24
Sandoz1$15
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$569 in reported general payments places this provider in the 25th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana →

Medicare billing

Part B allowed, 2024
$27,962
Medicare patients
69
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Baton Rouge

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →